January 7, 2022
Johnson & Johnson (J&J) announced the new results of the largest study to date on the durability of COVID-19 vaccines in the United States, showing that a single injection of the J&J COVID-19 vaccine resulted in lasting protection up to ” at six months against peak COVID-19 infections, hospitalizations and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of J&J and conducted in partnership with the Department of Science-Aetion, Inc, and the Division of Pharmacoepidemiology, Department of Medicine at Brigham and Women’s Hospital and Harvard Medical School.
“We continue to make significant efforts to study the sustainability of the protection offered by the Johnson & Johnson vaccine amid the ever-evolving COVID-19 pandemic,” said Mathai Mammen, MD, Ph.D., vice Executive Chairman, Pharmaceuticals, Janssen Research & Development LLC, J&J. “Although this data is changing rapidly, we are seeing vaccine efficacy against COVID-19-related hospitalizations of approximately 80% from a single injection of the J&J vaccine, and this level of protection remains stable throughout the period studied so far. at six months. The robust and sustained durability of our COVID-19 vaccine reflects its unique underlying immunology. We previously reported that our vaccine induces a strong antibody response as well as a particularly strong increase in T cells which is consistent between variants, including Omicron. “
The new study published on medRxiv extensively examined the durability profiles of the three vaccines licensed or approved in the United States using the same methodology for three outcomes of interest: COVID-19 infections, hospitalizations, and hospital admissions. intensive care.
The study showed that the effectiveness of the J&J COVID-19 vaccine against breakthrough infections and hospitalizations remained sustainable. The mRNA vaccines (two doses) have shown decreasing efficacy for hospitalizations and major infections. The three vaccines did not at any time show any evidence of decreased protection against COVID-19-related ICU admissions, showing sustained strong protection against extremely serious illnesses. The study was not designed to compare the durability of vaccines.
To access more business news, visit NJB News Now.